Dynamically Reprograms Mitochondrial Respiration to Augment Cuproptosis in Cancer Therapy

Why It Matters

By linking metabolic reprogramming with copper‑mediated cell death, the platform creates a potent, multi‑pathway anticancer approach that could overcome resistance to conventional therapies.

Key Takeaways

• Copper polymer delivers lactate oxidase into tumor cells.
• Lactate conversion raises mitochondrial respiration, triggering cuproptosis.
• DLAT oligomerization amplifies copper‑induced cell death.
• Fenton‑like reaction induces ferroptosis alongside cuproptosis.
• Nanoparticles show strong tumor regression in mouse models.

Pulse Analysis

The emergence of cuproptosis—a copper‑dependent form of regulated cell death—has opened new avenues for targeting cancer metabolism. Traditional therapies often ignore the tumor’s reliance on altered metabolic pathways, but this study leverages that dependency. By encapsulating lactate oxidase within a copper‑coordinated polymer, researchers deliver the enzyme directly to malignant cells, where it oxidizes abundant lactate into pyruvate. The resulting surge in pyruvate fuels the tricarboxylic acid cycle, boosting mitochondrial respiration and priming cells for copper‑induced toxicity.

Beyond merely enhancing respiration, the nanoparticles orchestrate a cascade of molecular events. Elevated mitochondrial activity promotes the oligomerization of dihydrolipoamide S‑acetyltransferase (DLAT), a key step that destabilizes the TCA cycle and accelerates cuproptosis. Concurrently, copper ions catalyze a non‑iron‑dependent Fenton‑like reaction, generating reactive oxygen species that trigger ferroptosis. This dual‑mode cell death strategy attacks tumors on two fronts, reducing the likelihood of adaptive resistance and offering a broader therapeutic window.

Preclinical trials in murine models demonstrated robust antitumor efficacy, with treated groups showing significant tumor shrinkage and prolonged survival compared to controls. The approach exemplifies how exploiting metabolic vulnerabilities can translate into tangible clinical benefits. As the oncology field seeks novel, mechanism‑driven therapies, copper‑polymer nanocarriers may soon advance to early‑phase human studies, potentially reshaping treatment paradigms for metabolically aggressive cancers.